CrossrefInfokarte
Recognition and management of organ-specific toxicities associated with enfortumab vedotin plus pembrolizumab and erdafitinib in locally advanced or metastatic urothelial carcinoma
Cancer Treatment Reviews · 2026-12 · 151 · 103233
DOI: 10.1016/j.ctrv.2026.103233 ↗Abstract
Kein Abstract verfügbar.
EUVIMED